Comparison of Effectiveness in Ciclesonide and Fluticasone Propionate on Small Airway Function in Mild Asthma  by Hoshino, Makoto
Allergology International Vol 59, No1, 2010 www.jsaweb.jp 59
Comparison of Effectiveness
in Ciclesonide and Fluticasone
Propionate on Small Airway
Function in Mild Asthma
Makoto Hoshino1,2
ABSTRACT
Background: Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but conventional ICS may
have limited effectiveness in inflammation and patency of small airways. Ciclesonide is delivered and deposited
in the peripheral region of the lung as a small particle corticosteroid. The aim of the study is to compare the ef-
fects of ciclesonide with fluticasone propionate on small airway function in asthma.
Methods: Thirty mild persistent asthma patients treated with 200 μg of fluticasone propionate were random-
ized to receive either ciclesonide 200 μg once daily or fluticasone propionate 100 μg twice daily for 8 weeks.
Small airway function was assessed by impulse oscillometry (IOS) and percentage of eosinophil induced spu-
tum.
Results: We observed that ciclesonide significantly improved IOS measured resistance of small airways (R5-
R20; p < 0.05), distal reactance (X5; p < 0.01), reactance area (AX; p < 0.01), and decreased late-phase spu-
tum eosinophil level (p < 0.01) compared with fluticasone propionate. There were no significant changes in spi-
rometry indices in either group during the study.
Conclusions: These findings suggest that ciclesonide improves small airway function and inflammation com-
pared with fluticasone propionate in mild asthma. This study provides evidence that IOS and late-phase in-
duced sputum allows detection of changes in the small airways that can not be detected by spirometry.
KEY WORDS
asthma, ciclesonide, fluticasone propionate, impulse oscillometry, sputum eosinophils
INTRODUCTION
Bronchial asthma is characterized by chronic inflam-
mation of the airways, and anti-inflammatory treat-
ment with inhaled corticosteroids (ICS) is recom-
mended as the first line therapy.1 This inflammation
usually affects the whole respiratory tract, from the
central to the peripheral airways and alveolar tis-
sues.2,3 Recently, there is strong evidence that small
airways significantly contribute to total airway resis-
tance and several studies have confirmed peripheral
airway involvement in asthma.4,5 This new insight in
the importance of small airway inflammation in
asthma has led to the introduction of ICS with small
particle sizes that target the site of inflammation.
Ciclesonide (Teijin Pharma, Tokyo, Japan), a novel
synthetic small-particle corticosteroid, is adminis-
tered as an aerosol using a hydrofluoroalkane (HFA)-
134a metered-dose inhaler (MDI), and the deposition
rate of it is high in the lung with only minimum depo-
sition in the oropharynx area.6 Additionally, two-
dimensional gamma scintigraphy and three-
dimensional single photon emission computed to-
mography showed that mean percent deposition in
peripheral regions was higher than in central re-
gions.7 Clinical studies show that ciclesonide signifi-
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cantly improves pulmonary function8-10 and reduces
airway inflammation in patients with asthma.11 Re-
cently, Cohen et al.12 reported that ciclesonide im-
proved small airway parameters reflecting alveolar
exhaled nitric oxide and airway trapping on com-
puted tomography, though it is still unknown for
other small airway function and inflammation. Flutica-
sone propionate (GlaxoSmithKline, Tokyo, Japan)
dry powder inhaler (DPI) is one of the most widely
used ICS in the treatment of asthma and is more cen-
trally deposited in the lung because of the larger par-
ticle size.13 The importance of ICS distribution
throughout the whole lung must be acknowledged
when patients with stable control asthma are being
maintained with fluticasone propionate.
Spirometry is widely used to assess improvements
of lung function, but these data are often insensitive
to physiological changes such as in mild asthmatic
patients.14 Impulse oscillometry (IOS) is a technique
used to measure respiratory resistance (R) and reac-
tance (X) at each frequency. IOS also provides data
with respect to separate measurements for both large
and small airway function.15
Induced sputum has been introduced as a reliable,
valid, and responsible method to safely obtain airway
secretions.16 Corrected sputum early in an inhalation
period more clearly reflects proximal airway condi-
tions, in contrast to late-phase sputum which reflects
peripheral airways.17
Although the clinical efficacy of ciclesonide and flu-
ticasone propionate was equivalent,18 there is no
study to compare the effect of these drugs on large
and small airway resistance separately. We evaluate
the efficacy of ciclesonide on small airway function
and inflammation assessed by IOS and induced spu-
tum in patients with mild asthma already being
treated with fluticasone propionate.
METHODS
SUBJECTS
Asthma patients were non-smokers, and had a clear
history of relevant symptoms, with documented re-
versible airway obstruction (>12% improvement in
forced volume in one second [FEV1] either spontane-
ously or after administration of inhaled β2 agonists).
Asthma was defined according to the American Tho-
racic Society criteria. All patients attending the hospi-
tal had step 2 severity of asthma,1 and who presented
with stable symptoms for at least 3 months by using
dry powder type ICS. Atopy was diagnosed by the
presence of one or more specific serum IgE antibod-
ies against common inhalant allergens. The study
was approved by the ethics committee of St. Mari-
anna University School of Medicine, and informed
written consent to study protocol was obtained from
all subjects.
STUDY DESIGN
All patients were treated with fluticasone propionate
(GlaxoSmithKline) 100 μg twice daily during an 8
week run-in period. At the end of the run-in period,
baseline measurements of pulmonary function and
sputum induction were performed. Using the enve-
lope method, eligible patients were randomly allo-
cated to either ciclesonide (Teijin Pharm, Tokyo, Ja-
pan) 200 μg once daily or fluticasone propionate 100
μg twice daily for an 8 week treatment period. The
envelopes were opened by an independent pharma-
cist involved in neither the diagnosis nor treatment of
the patients evaluated. No other asthma medications
were permitted except for inhaled β2 agonists as re-
quired. Pulmonary function and induced sputum
were repeated after 8 weeks of treatment. Asthma
symptoms and control were evaluated with the
asthma control test (ACT) developed by QualityMet-
ric Incorporated.19 The patients showed good compli-
ance and adherence to treatment with either cicleson-
ide or fluticasone propionate.
PULMONARY FUNCTION MEASUREMENTS
Spirometry and IOS study was done according to the
ERS task force recommendations.20 The measure-
ments of spirometry function (FEV1, FEV1forced vi-
tal capacity [FVC], forced expiratory flow 25-75%
[FEF25-75%], maximum expiratory flow rate at 50%
[MEF50%] and 25% of FVC [MEF25%]) were con-
ducted by FUDAK-77 (Fukuda Electronics, Tokyo,
Japan). These parameters except for FEV1FVC are
expressed as percentages of predicted values accord-
ing to the prediction equations of the Japanese Soci-
ety of Chest Disease.21 For IOS, MasterScreen IOS
(Jaeger, Wurzburg, Germany) was used. Five IOS pa-
rameters were evaluated: (1) airway resistance at 5
Hz (R5), a total index influenced both large and small
airways; (2) airway resistance at 20 Hz (R20), an in-
dex of large airways; (3) subtracting R5 from R20 (R5-
R20), an index of frequency dependence of resis-
tance, reflective of small airways function; (4) reac-
tance at 5 Hz (X5), which is considered to indicate
the capacitive reactance in small airways; and (5) an
integrated area of low-frequency reactance
(AX).15,22,23 This parameter included all negative val-
ues of respiratory reactance between 5 Hz and the
frequency at which reactance is zero, and may reflect
small airway function.15
SPUTUM INDUCTION AND PROCESSING
After inhalation of 200 μg of salbutamol via a metered
dose inhaler, the subjects inhaled 5% hypertonic sa-
line for 15 minutes using an ultrasonic nebulizer (NE-
U22, Omron, Tokyo, Japan) and all induced samples
were sequentially collected over 30 minutes. We re-
garded the first induced sputum samples during 15
minutes of inhalation as early-phase samples, while
those finally collected after inhalation were taken as
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Table 1 Patients characteristics
P-valueFluticasone propionate groupCiclesonide group
1614Subjects (n)
0.5276/106/8Gender (Male/Female)
0.17445.3 ± 14.150.1 ± 14.7Age (years)
0.29012.3 ± 13.09.8 ± 9.7Disease duration (years)
0.54213/310/4Atopy/Non-atopy
Data are expressed as mean ± SD
Table 2 Spirometry function data at baseline and after treatment with ciclesonide or fluticasone propionate
Fluticasone propionate groupCiclesonide group
P-valueAfterBeforeP-valueAfterBefore
0.73899.7 ± 16.898.6 ± 18.20.65793.7 ± 11.491.9 ± 1.5FEV1 (%predicted)
0.88475.1 ± 6.975.0 ± 7.10.71375.2 ± 2.273.6 ± 11.6FEV1/FVC (%)
0.70958.2 ± 34.258.5 ± 21.50.16559.6 ± 18.853.9 ± 30.4FEF25-75 (%predicted)
0.79153.7 ± 29.655.2 ± 16.90.09257.2 ± 18.150.9 ± 7.8MEF50 (%predicted)
0.67836.3 ± 12.737.7 ± 18.70.16139.2 ± 7.635.4 ± 23.2MEF25 (%predicted)
Data are expressed as mean ± SD.
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF25-75, forced expiratory flow 25-75%; MEF50, maximum 
expiratory flow rate at 50% of FVC; MEF25, maximum expiratory flow rate at 25% of FVC.
late-phase samples. Adequate plugs of sputum were
separated from saliva. Sputum was transferred in
small amounts and finely distributed and smeared
onto microscopic slides. Each smear was air dried
and stained with May-Grunwald-Gimsa, and differen-
tial cell counts were obtained from 400 non-squamous
cells by a blinded investigator.
STATISTICAL ANALYSIS
Data are expressed as mean ± SD. All statistical analy-
ses were performed using Stat View software (SAS
Institute, Cary, NC, USA). The results of data were
analyzed by using the paired t test, or its equivalent
non-parametric Wilcoxon’s singed-rank test for IOS
parameters with non-normal distribution. Significance
was established at a p < 0.05 (two-tailed).
RESULTS
A total of 36 patients were approached and agreed to
participate in the study. Six patients were unable to
tolerate the hypertonic saline challenge. None of
them occurred in asthma attack, but these patients
were again treated with 200 μg salbutamol after hy-
pertonic inhalation method. Fourteen patients in the
ciclesonide group and 16 patients in the fluticasone
propionate group completed the study. Patients’ char-
acteristics are shown in Table 1. There was no signifi-
cant difference between the two groups in terms of
clinical data.
The values of spirometry measurements at base-
line and 8 weeks after treatment are given in Table 2.
None of the spirometry indices showed significant
changes in either the ciclesonide or the fluticasone
propionate group. At baseline, no significant differ-
ences in IOS parameters were observed in patients
who were assigned to ciclesonide or fluticasone
propionate treatment groups. There were significant
improvements in airway resistance R5 (0.35 ± 0.10 to
0.31 ± 0.09 kPaLs; p < 0.05), R5-R20 (0.08 ± 0.07 to
0.06 ± 0.06 kPaLs; p < 0.05), reactance X5 (-0.14 ±
0.04 to -0.10 ± 0.04 kPaLs; p < 0.01), and reactance
area AX (0.61 ± 0.52 to 0.44 ± 0.42 kPaL; p < 0.01) ex-
cept for R20 in the ciclesonide group. However, IOS
parameters remained unchanged in the fluticasone
propionate group (Fig. 1).
In the ciclesonide group, eosinophil percentage in
the late-phase sputum significantly decreased from
12.2 ± 6.9% to 6.9 ± 3.2% (p < 0.01), but did not de-
crease in the early-phase sputum. In contrast, there
were no significant changes in sputum eosinophils in
the fluticasone propionate group (Fig. 2).
The ACT scores in the ciclesonide group signifi-
cantly improved from 21.2 ± 1.9 to 23.3 ± 1.2 (p <
0.01) and use of rescue β2 inhalation mainly de-
creased in the 5 items of ACT, however no significant
improvements were seen for ACT scores in the flu-
ticasone propionate group (Fig. 3).
DISCUSSION
We demonstrated that treatment with 200 μg cicle-
sonide once daily can specifically improve parameters
reflecting patency and inflammation of small airways
in mild asthmatic patients who were treated with 100
μg fluticasone propionate twice daily, even though
they were stable from clinical symptoms and ordinary
pulmonary function. In order to compare the effects
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Fig. 1 Changes in impulse oscilometry (IOS) measured airway resistance of R5, 
R20, R5-R20, reactance X5, and reactance area (AX) in the ciclesonide- and flu-
ticasone propionate-treated groups. R5, airway resistance at 5 Hz; R20, airway re-
sistance at 20 Hz; R5-R20, airway resistance at 5 to 20 Hz; X5, airway reactance at 
5 Hz; AX, integrated area of low frequency reactance. Horizontal bars represent 
mean values.
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Fig. 2 Changes in eosinophil percentage of early- and late-phase sputum in the ciclesonide- and flutica-
sone propionate-treated groups. Horizontal bars represent mean values.
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Fig. 3 Changes in asthma control test (ACT) scores in the ciclesonide- and fluticasone propionate-
treated groups. Columns and vertical bars represent mean ± SD.
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of ciclesonide with fluticasone propionate on small
airway function, we selected mild persistent asthma
treatment with ICS alone, because most asthmatic pa-
tients with more step 3 severity had already been
medicated with other long-acting β2 agonists, andor
leukotriene receptor antagonists.
In the last decade, therapeutic research related to
asthma specially focused on targeting small airways.
The sizes of ICS particles strongly affected the aero-
dynamic properties of the drugs and its delivery to
distal airways.24 Among the ICS, fluticasone
propionate-DPI has the largest mass median aerody-
namic diameter (MMAD of 5.4 μm) and deposited in
the lungs with 10 to 16%.13 In contrast, the ciclesonide
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HFA-MDI delivers small particles (MMAD of 0.9 μm)
and achieves delivery of >50% of ciclesonide dose to
the lung.6,7 As well, the small particle size of HFA-
beclomethasone dipropionate (BDP) has resulted in
improved lung deposition with 50 to 60% of the emit-
ted of deposited throughout the airways.25 Our re-
sults showed the lack of significant changes in spi-
rometry function data between ciclesonide and flu-
ticasone propionate treated groups. It had been re-
ported that ciclesonide did not significantly improve
small airway parameters such as FEF25-75 and clos-
ing volume.12 However, some of the small airway pa-
rameters had a large variability, thus reducing statis-
tical power. Furthermore, spirometric data are most
commonly reported due in part to the large volume of
information on the use of tests such as FEV1 meas-
urement. The IOS is more sensitive in measuring
small airway dysfunction and recognizing subtle
changes in the airways.14,26 Frequency dependent
changes in resistance have been demonstrated in
small airway disease.27 The difference between R5
and R20 (R5-R20) as an index of frequency depend-
ence of resistance was reported to be a sensitive in-
dex of peripheral airway obstruction.22 As inductive
reactance is negligible at low frequency, X5 can be
considered as capacitive reactance and reflects small
airway dysfunction.28,29 AX is an index of small airway
obstruction complementary to frequency dependence
of resistance. The close correlation among spiromet-
ric values of FEF25-75 and these IOS parameters are
consistent with these indices reflecting small airway
function.22 Thus the changes in R5-R20, X5, and AX in
this study indicate beneficial small airway effects
caused by reaching ciclesonide to the distal airways.
Assessment of respiratory mechanics over time with
IOS might offer important information about the pul-
monary response of asthmatic patients to therapy that
is not reflected by spirometric measurements.
The eosinophil percentage in late-phase sputum
showed a significant decrease after treatment with ci-
clesonide compared with fluticasone propionate. It
has been demonstrated that the eosinophil percent-
ages in induced sputum was significantly correlated
with those in water obtained by bronchial washing,
and bronchoalveolar lavage, suggesting that sputum
was useful to evaluate the airway inflammation.30
According to the study of Gershman et al.,17 in spu-
tum collected at each 4 minute interval during 20
minute induction by inhaling 3% saline, sputum sam-
ples in early-phase showed higher concentrations of
mucin-like proteins originating from proximal air-
ways, while sputum samples collected 12 minutes af-
ter inhalation contained higher levels of surfactant
protein (SP)-A, which is more likely to exist in the pe-
ripheral airway alveoli. Although we did not measure
SP-A values, we suppose that the 5% hypertonic saline
inhalation technique has similar results.31 The large
airway compartment of the lung was sampled in the
early phase by sputum induction, and the smaller air-
ways were sampled in the late phase. We found that
in asthma being maintained with fluticasone propion-
ate administration, residual peripheral eosinophilic in-
flammation was ameliorated by switching to cicleson-
ide. Our findings are in agreement with a study by
Ohbayashi et al. who found that fine particle sizes of
ICS (HFA-BDP) can more effectively suppress
eosinophilic inflammation in the peripheral airways
for longer term treatment with fluticasone propionate
in asthma.32 Using surgically resected lung speci-
mens from asthmatic patients, eosinophils were sig-
nificantly reduced by treatment with chlorofluo-
rocarbon-BDP or fluticasone propionate in the large
airways, but not in the small airways.33 Hauber et al.
reported that HFA-flunisolide (MMAD of 1.2 μm) ef-
fectively reduced eosinophilic inflammation in small
airways by transbronchial biopsy.34 Our results raise
the possibility that ciclesonide may be more effective
than fluticasone propionate for improving function in
the small airways of asthmatic patients through more
effective suppression of peripheral airway inflamma-
tion.
We observed a significant increase of ACT scores
after switching fluticasone propionate to ciclesonide.
The ACT is a patient administered survey for assess-
ing asthma symptoms, nocturnal symptoms, rescue
medications, and role limitations.19 The ACT score is
reliable, valid, and responsive to changes in asthma
control over time. Although all asthmatic patients
showed good compliance and adherence, it may be a
possible reason for the difference of drug compliance
and side effects between once daily ciclesonide and
twice daily fluticasone propionate. Our findings show
that the improvement in symptom control after treat-
ment with ciclesonide contributes to changes in pul-
monary function and inflammation. Although all asth-
matic patients showed good compliance and adher-
ence, it may be a possible reason for the difference of
drug compliance and side effects between once daily
ciclesonide and twice daily fluticasone propionate.
Current asthma guidelines do not recommend pre-
ventative treatment for asthma, but our study war-
rants evaluating the degree of involvement of small
airways and their response to other ICS therapy.
In conclusion, we have demonstrated that cicleson-
ide improves both small airway function and inflam-
mation in patients with mild asthma treated with flu-
ticasone propionate. These beneficial findings sug-
gest that IOS and the late-phase induced sputum with
hypertonic saline are useful tools to assist in diagnos-
ing and monitoring small airway involvements in
asthma.
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